Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Afatinib / pharmacology
  • Afatinib / therapeutic use*
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Disease Progression
  • Drug Resistance, Neoplasm / drug effects*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Afatinib